Abdallah G. Kfoury

TL;DR: Institutional Affiliations Chair Costanzo MR: Midwest Heart Foundation, Lombard Illinois, USA Task Force 1 Dipchand A: Hospital for Sick Children, Toronto Ontario, Canada; Starling R: Cleveland Clinic Foundation, Cleveland, Ohio, USA; Starlings R: University of Chicago, Chicago, Illinois,USA; Chan M: university of Alberta, Edmonton, Alberta, Canada ; Desai S: Inova Fairfax Hospital, Fairfax, Virginia, USA.

TL;DR: Among patients with acute decompensated heart failure, there were no significant differences in patients' global assessment of symptoms or in the change in renal function when diuretic therapy was administered by bolus as compared with continuous infusion or at a high dose asCompared with a low dose.

TL;DR: Outcomes of DT in the post-REMATCH era in the United States are described, finding that patients with advanced heart failure who are referred for DT before major complications of heart failure develop have the best chance of achieving an excellent 1-year survival with LVAD therapy.

TL;DR: Among selected patients who had received a cardiac transplant more than 6 months previously and who were at a low risk for rejection, a strategy of monitoring for rejection that involved gene-expression profiling, as compared with routine biopsy was not associated with an increased risk of serious adverse outcomes and resulted in the performance of significantly fewer biopsies.

TL;DR: In this article, the authors developed a risk score for right ventricular failure after left ventricular assist device (LVAD) implantation, which was defined by the need for inhaled nitric oxide for ≥48 hours or intravenous inotropes for >14 days.